首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Liver Cancer

Liver Cancer杂志,由S. Karger AG出版,于2012年创刊,4 issues/year,出版语言English,ISSN:2235-1795,E-ISSN:1664-5553。

投稿咨询
Liver Cancer
Liver Cancer
Liver Cancer
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
10.5
CiteScore
17
期刊收录
SCI、SCIE

Liver Cancer(中文译名:《肝癌》),ISSN:2235-1795,EISSN:1664-5553,是S. Karger AG出版的国际性学术期刊,创刊于2012年,以4 issues/year形式稳定发行,2026年总发文量约66篇。该刊采用OA开放访问,学科归属为Medicine - Oncology。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达10.5,2025年期刊CiteScore为17,2025年期刊自引率约10.5%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Liver Cancer长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期16 Weeks,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,JapanCHINA MAINLAND、Taiwan、South Korea、USA、Italy、GERMANY (FED REP GER)等为核心发文国家与地区;KINDAI UNIVERSITY (KINKI UNIVERSITY)NATIONAL TAIWAN UNIVERSITY、OGAKI MUNICIPAL HOSPITAL、SEOUL NATIONAL UNIVERSITY (SNU)、TAIPEI VETERANS GENERAL HOSPITAL、UNIVERSITY OF ULSAN、EHIME PREFECTURAL CENT HOSP等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学 GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学
2区 2区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学 ONCOLOGY 肿瘤学
2区 2区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学 ONCOLOGY 肿瘤学
1区 1区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q1 11 / 153

93.1

学科:ONCOLOGY SCIE Q1 36 / 333

89.3

学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q1 13 / 153

91.83

学科:ONCOLOGY SCIE Q1 34 / 333

89.94

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q1 9 / 143

94.1

学科:ONCOLOGY SCIE Q1 23 / 322

93

学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q1 10 / 143

93.36

学科:ONCOLOGY SCIE Q1 22 / 322

93.32


中国学者近期发文

1
Impact of Procedural Quality on Outcomes of Transarterial Chemoembolization for Hepatocellular Carcinoma: A Multicenter Stud

Author:Jiang, Nan; Zhang, Wen; Peng, Zhenwei; Liu, Chang; Xiao, Yu-Dong; Yang, Wei-Zhu; Ding, Rong; Yin, Li-Nan; Jiang, Jian-Qiang; Ni, Cai-Fang; Yan, Zhi-Ping; Kuang, Ming; Teng, Gao-Jun; Zhong, Bin-Yan

Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000550734

2
Impact of Age on Patient-Reported Outcomes with First-Line Camrelizumab plus Rivoceranib versus Sorafenib in Adults with Unresectable Hepatocellular Carcinoma: Post Hoc Analyses of the CARES-310 Open-Label, Randomized, Phase 3 Tria

Author:Chan, Stephen Lam; Kaseb, Ahmed Omar; Alexander, Laura; Meng, Xianzhang; Ryan, Kristin; Shi, Wei; Vogel, Arndt

Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000551156

3
Age-Adjusted Charlson Comorbidity Index Guides Risk Stratification for Hepatocellular Carcinoma Patients Treated with TACE Combined with Immune Checkpoint Inhibitors and Targeted Therapy: A Multicenter Retrospective Cohort Stud

Author:Lin, Xiaohan; Zhang, Shiying; Ong, Meiching; Fang, Jun; Mu, Aibo; Wang, Kui; Xu, Li; Bi, Xinyu; Liu, Xiufeng; Chen, Yongjun; Sun, Huichuan; Ling, Qi

Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000550356

4
Gd-EOB-DTPA-Enhanced Magnetic Resonance Imaging for Predicting Immunotherapy Response in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysi

Author:Xie, Wenbo; Sun, Linmao; Fu, Yumin; Liang, Shuhang; Liu, Yao; Wang, Jiabei; Liu, Lianxin

Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000550938

5
Survival Outcomes, Recurrence Patterns, and Its Corresponding Therapeutic Management after Conversion Therapy Followed by Curative Resection for Hepatocellular Carcinoma: A Real-World Stud

Author:Xiao, Rui; Yang, Zhenyun; Zheng, Zehao; Liu, Na; Yu, Wei; Lin, Qingyang; Chen, Jinbin; Wang, Juncheng; Zhou, Zhongguo; Zhang, Yaojun; Chen, Minshan; Hu, Dandan

Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000550954

6
Stable Disease without Tumor Shrink Cannot Benefit from Surgery following Immune-Based Therapy in Potentially Resectable Hepatocellular Carcinom

Author:He, Tian; Xu, Bin; Yang, Zi-Yue; Zhou, Shi-Qi; Wang, Zi-Yi; Wang, Lu-Na; Zhong, Cheng-Jie; Shi, Huan-Chen; Li, Hui; Hu, Bo; Zhu, Xiao-Dong; Shen, Ying-Hao; Gao, Qiang; Zhou, Jian; Fan, Jia; Sun, Hui-Chuan; Huang, Cheng

Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000550497

7
Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Stud

Author:Pan, Zhaolong; Liu, Dongming; Cao, Junbo; Fu, Linlin; Zhang, Xihao; Zhu, Xiaodong; Pan, Yangxun; Liu, Jianwei; Han, Chuangye; Jin, Renan; Shen, Shunli; Zhang, Xiaoyun; Liu, Hongzhi; Yang, Xiaobo; Hu, Kuan; Shi, Xiaoyi; Wang, Dongxu; Zhao, Yang; Zhong, Jianhong; Xiang, Bangde; Gu, Shanzhi; Li, Tao; Zhang, Shuijun; Zhou, Ledu; Zhao, Haitao; Zeng, Yongyi; Wen, Tianfu; Kuang, Ming; Liang, Xiao; Peng, Tao; Wang, Kui; Xu, Li; Li, Huikai; Song, Tianqiang; Sun, Huichuan; Zhang, Wei

Journal: LIVER CANCER. 2025; Vol. , Issue , pp. -. DOI: 10.1159/000545545

8
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Stud

Author:Yang, Da-Long; Peng, Ning; Nong, Jun-Liang; Chen, Kang; Su, Ze; Yu, Ya-Qun; Ye, Lin; Zeng, Fan-Jian; Liu, Shao-Ping; Yan, Yi-He; Wang, Xue-Yao; Yao, Hong-Bing; Yang, Fu-Quan; Li, Wen-Feng; Qin, Chuang; Wu, Ming-Song; Yang, Yong-Yu; Dong, Xiao-Feng; Li, Mian-Jing; Liu, Jie; Liang, Yong-Rong; Wu, Pei-Sheng; Zhong, Teng-Meng; Lai, Yong-Cheng; Chen, Yao-Zhi; Pang, Qing-Qing; Wang, Guo-Dong; Li, Fu-Xin; Mao, Xian-Shuang; Chen, Shu-Chang; Ou, Jun-Jie; Huo, Rong-Rui; Liang, Xiu-Mei; Xiang, Bang-De; Ma, Liang; Zhong, Jian-Hong

Journal: LIVER CANCER. 2025; Vol. , Issue , pp. -. DOI: 10.1159/000546052

9
Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinom

Author:Zhang, Yi-Min; Wu, Xin-Tong; Yi, Jun-Zhe; Xu, Jie; Zhang, Yu-Nan; Lyu, Ning; Zhao, Ming

Journal: LIVER CANCER. 2025; Vol. , Issue , pp. -. DOI: 10.1159/000545891

10
Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinom

Author:Shiina, Shuichiro; Tateishi, Ryosuke; Choi, Joon Il; Kim, So Yeon; Meng, Zhiqiang; Shen, Lujun; Lu, Sheng-Nan; Hwang, Jen-I.; Tobari, Maki; Maruyama, Hitoshi; Batsaikhan, Terguunbileg; Deng, Qing; Canseco, Lariza Marie; Asaoka, Yoshinari; Lin, Shi-Ming; Huang, Kai-Wen; Rhim, Hyunchul; Liang, Ping; Pua, Uei; Tanaka, Masatoshi; Wu, Peihong

Journal: LIVER CANCER. 2025; Vol. , Issue , pp. -. DOI: 10.1159/000544976


在线咨询

Liver Cancer

国际简称:LIVER CANCER参考译名:肝癌

年发文量:66 CiteScore:17 是否预警:否 Gold OA文章占比:100.00% 研究类文章占比:86.36%

杂志社联系方式:ALLSCHWILERSTRASSE 10, BASEL, SWITZERLAND, CH-4009

Liver Cancer